Best of the Week
Most Popular
1. TESLA! Cathy Wood ARK Funds Bubble BURSTS! - 12th May 21
2.Stock Market Entering Early Summer Correction Trend Forecast - 10th May 21
3.GOLD GDX, HUI Stocks - Will Paradise Turn into a Dystopia? - 11th May 21
4.Crypto Bubble Bursts! Nicehash Suspends Coinbase Withdrawals, Bitcoin, Ethereum Bear Market Begins - 16th May 21
5.Crypto Bubble BURSTS! BTC, ETH, XRP CRASH! NiceHash Seizes Funds on Account Halting ALL Withdrawals! - 19th May 21
6.Cathy Wood Ark Invest Funds Bubble BURSTS! ARKK, ARKG, Tesla Entering Severe Bear Market - 13th May 21
7.Stock Market - Should You Be In Cash Right Now? - 17th May 21
8.Gold to Benefit from Mounting US Debt Pile - 14th May 21
9.Coronavius Covid-19 in Italy in August 2019! - 13th May 21
10.How to Invest in HIGH RISK Tech Stocks for 2021 and Beyond - Part 2 of 2 - 18th May 21
Last 7 days
Virgin Media Fibre Broadband Installation - What to Expect, Quality of Wiring, Service etc. - 21st Jun 21
Feel the Inflationary Heartbeat - 21st Jun 21
The Green Superfuel That Could Disrupt Global Energy Markers - 21st Jun 21
How Binance SCAMs Crypto Traders with UP DOWN Coins, Futures, Options and Leverage - Don't Get Bogdanoffed! - 20th Jun 21
Smart Money Accumulating Physical Silver Ahead Of New Basel III Regulations And Price Explosion To $44 - 20th Jun 21
Rambling Fed Triggers Gold/Silver Correction: Are Investors Being Duped? - 20th Jun 21
Gold: The Fed Wreaked Havoc on the Precious Metals - 20th Jun 21
Investing in the Tulip Crypto Mania 2021 - 19th Jun 21
Here’s Why Historic US Housing Market Boom Can Continue - 19th Jun 21
Cryptos: What the "Bizarre" World of Non-Fungible Tokens May Be Signaling - 19th Jun 21
Hyperinflationary Expectations: Reflections on Cryptocurrency and the Markets - 19th Jun 21
Gold Prices Investors beat Central Banks and Jewelry, as having the most Impact - 18th Jun 21
Has the Dust Settled After Fed Day? Not Just Yet - 18th Jun 21
Gold Asks: Will the Economic Boom Continue? - 18th Jun 21
STABLE COINS PONZI Crypto SCAM WARNING! Iron Titan CRASH to ZERO! Exit USDT While You Can! - 18th Jun 21
FOMC Surprise Takeaways - 18th Jun 21
Youtube Upload Stuck at 0% QUICK FIXES Solutions Tutorial - 18th Jun 21
AI Stock Buying Levels, Ratings, Valuations Video - 18th Jun 21
AI Stock Buying Levels, Ratings, Valuations and Trend Analysis into Market Correction - 17th Jun 21
Stocks, Gold, Silver Markets Inflation Tipping Point - 17th Jun 21
Letting Yourself Relax with Activities That You Might Not Have Considered - 17th Jun 21
The Federal Reserve and Inflation - 16th Jun 21
Inflation Soars 5%! Will Gold Skyrocket? - 16th Jun 21
Stock Market Sentiment Speaks: Inflation Is For Fools - 16th Jun 21
Four News Events That Could Drive Gold Bullion Demand - 16th Jun 21
5 ways that crypto is changing the face of online casinos - 16th Jun 21
Transitory Inflation Debate - 15th Jun 21
USDX: The Cleanest Shirt Among the Dirty Laundry - 15th Jun 21
Inflation and Stock Market SPX Record Highs. PPI, FOMC Meeting in Focus - 15th Jun 21
Stock Market SPX 4310 Right Around the Corner! - 15th Jun 21
AI Stocks Strength vs Weakness - Why Selling Google or Facebook is a Big Mistake! - 14th Jun 21
The Bitcoin Crime Wave Hits - 14th Jun 21
Gold Time for Consolidation and Lower Volatility - 14th Jun 21
More Banks & Investors Are NOT Believing Fed Propaganda - 14th Jun 21
Market Inflation Bets – Squaring or Not - 14th Jun 21
Is Gold Really an Inflation Hedge? - 14th Jun 21
The FED Holds the Market. How Long Will It Last? - 14th Jun 21
Coinbase vs Binance for Bitcoin, Ethereum Crypto Trading & Investing During Bear Market 2021 - 11th Jun 21
Gold Price $4000 – Insurance, A Hedge, An Investment - 11th Jun 21
What Drives Gold Prices? (Don't Say "the Fed!") - 11th Jun 21
Why You Need to Buy and Hold Gold Now - 11th Jun 21
Big Pharma Is Back! Biotech Skyrockets On Biogen’s New Alzheimer Drug Approval - 11th Jun 21
Top 5 AI Tech Stocks Trend Analysis, Buying Levels, Ratings and Valuations - 10th Jun 21
Gold’s Inflation Utility - 10th Jun 21
The Fuel Of The Future That’s 9 Times More Efficient Than Lithium - 10th Jun 21
Challenges facing the law industry in 2021 - 10th Jun 21
SELL USDT Tether Before Ponzi Scheme Implodes Triggering 90% Bitcoin CRASH in Cryptos Lehman Bros - 9th Jun 21
Stock Market Sentiment Speaks: Prepare For Volatility - 9th Jun 21
Gold Mining Stocks: Which Door Will Investors Choose? - 9th Jun 21
Fed ‘Taper’ Talk Is Back: Will a Tantrum Follow? - 9th Jun 21
Scientists Discover New Renewable Fuel 3 Times More Powerful Than Gasoline - 9th Jun 21
How do I Choose an Online Trading Broker? - 9th Jun 21
Fed’s Tools are Broken - 8th Jun 21
Stock Market Approaching an Intermediate peak! - 8th Jun 21
Could This Household Chemical Become The Superfuel Of The Future? - 8th Jun 21
The Return of Inflation. Can Gold Withstand the Dark Side? - 7th Jun 21
Why "Trouble is Brewing" for the U.S. Housing Market - 7th Jun 21
Stock Market Volatility Crash Course (VIX vs VVIX) – Learn How to Profit From Volatility - 7th Jun 21
Computer Vision Is Like Investing in the Internet in the ‘90s - 7th Jun 21
MAPLINS - Sheffield Down Memory Lane, Before the Shop Closed its Doors for the Last Time - 7th Jun 21
Wire Brush vs Block Paving Driveway Weeds - How Much Work, Nest Way to Kill Weeds? - 7th Jun 21
When Markets Get Scared and Reverse - 7th Jun 21
Is A New Superfuel About To Take Over Energy Markets? - 7th Jun 21

Market Oracle FREE Newsletter

How to Protect your Wealth by Investing in AI Tech Stocks

Biotech Stocks With Near Term Catalysts

Companies / BioTech Jul 18, 2019 - 01:31 AM GMT

By: Joshua_Rodriguez

Companies Medical innovation is an incredible thing. In fact, as we continue to better understand the human body and cutting-edge biotechnology companies continue to produce innovative medicines, the average life expectancy in human beings is growing at a rate of about two months every year.

Not only is this innovation in medicine leading to a better quality of life and longer lifespan for countless patients, it is also leading strong investment opportunities. Driven by the fact that there are multiple catalysts along the process of drug development and incredible value once new drugs are approved, investor interest in the field of biotechnology is running high.

Many of these strong opportunities arise when biotechnology companies release news surrounding clinical progress, regulatory updates, and commercial success, some of the most common catalysts in the space. With that said, here’s a list of biotechnology companies with several catalysts ahead.

Amarin (AMRN): A Label Expansion Could Be Seriously Big News!

Amarin Corporation is best known for its flagship fish-oil drug, Vascepa. The treatment, approved for patients with high triglyceride levels, is already being met with strong uptake in the market. In fact, in a mid-year update published in early July, Amarin increased its revenue guidance from a midpoint of $350 million to a midpoint of $400 million, a move driven by expectations of strong Vascepa sales.

Nonetheless, the strong sales expectations may just be the tip of the iceberg should all go well with a coming catalyst. In September of last year, Amarin released the results of its Reduce-It cardiovascular outcomes study. The results proved to be impressive, suggesting decreased risk of cardiovascular complications among patients taking Vascepa.

Following these strong results, Amarin submitted a supplemental New Drug Application to the FDA looking to expand its label to include the reduction of cardiovascular risk in high risk patients as an indication. In late September, the FDA will be making its decision, and if positive, the stock could skyrocket. 

Previously, patients in the high cardiovascular risk category generally maintained heart health with once-daily baby aspirin. However, after the American Heart Association retracted this recommendation, there were no widely accepted options on the market, making the potential market opportunity massive.

Considering the strong sales growth that we’ve seen from Vascepa, any sales reports will likely prove to be catalystic events. Moreover, investors should watch closely as we near September, as the biggest catalyst of the company’s history may be hitting at the end of the month!

Hemispherx Biopharma (HEB): Multiple Data Readouts On The Horizons

Hemispherx biopharma is an immunopharma company. This means that the company is focused on innovative therapies that provide the body’s own immune system with the tools needed in order to fight some of the most devastating medical conditions.

Most notably is the company’s work in the field of immuno-oncology. This is an area where immunotherapies are used to enhance the body’s immune system, giving it the ability to fight against cancer.

In particular, Hemispherx Biopharma is working on a treatment option known as Ampligen. Approved in Argentina as an option for patients with myalgic encephalomyelitis/chronic fatigue syndrome, or ME/CFS, the treatment has already been approved for an indication not addressed by any other therapy on the market. While this is impressive in and of itself, I find the company’s work in the clinical setting to be far more meaningful.

Data from studies in both a wide variety of animal models of cancer, as well as in human subjects, suggests that Ampligen may modulate the tumor microenvironment. This microenvironment modulation has the potential to provide broad spectrum enhancement of the immune system to target and eliminate cancer cells.

Also, it seems as though Ampligen may be a double-edged sword in the fight against cancer. Data suggests efficacy as not only a mono-therapy, but potentially a combination therapy. In fact, data from various preclinical and clinical studies suggests synergies between Ampligen and immune-blockade inhibitor drugs. As such, it is believed that through the synergistic support provided by Ampligen to checkpoint inhibitors, these treatment options may see an increase in efficacy.

Due to the data suggesting potential efficacy in enhancing the treatment of a wide range of cancers, Ampligen is being studied across multiple programs in a robust series of clinical trials. With active clinical trials in ovarian, colorectal, and breast cancers, as well as plans for studies in renal cell carcinoma and melanoma, there are several catalysts to watch for ahead from Hemispherx.

BioMarin (BMRN): Multiple Catalysts And Political Safehaven

BioMarin is an interesting play. The biotechnology company is focused on the development of drugs for ultra-rare conditions. This strategy is smart for two reasons. First and foremost, treatments for ultra-rare diseases tend to move through the regulatory process faster and become instant market leaders when approved, as few to no options already exist.

Perhaps more importantly, given the political climate, treatments for rare conditions with limited population pools have a greenlight when it comes to commanding a high price tag. Election day is just over a year away, and early debates suggest that drug price reform will be a top priority on the checklist for Democrats.

However, due to the targeted rare indications, BioMarin is shielded from the risk associated with this reform. This ultimately separates the company from the majority of its biotechnology peers, giving it a strategic advantage.

At the moment, BioMarin has six revenue producers. The most recently launched option, Palynziq, is designed as a treatment for a rare condition known as phenylketonuria. In the first quarter, the drug generated $12.3 million in sales, and this figure is expected to climb to $100 million for the full 2019 year.

The company also has several established therapies on the market, including Vimizim, Kuvan, and Naglazyme, which are generating strong sales growth of their own.

Moving forward, the company’s treatment under development showing the most promise is a hemophilia A candidate known as valoctocogene roxaparvovec. Should this treatment be approved, it could push BioMarin to the next level, offering access to a market that is expected to grow to be worth nearly $17 billion in the years to come.

Considering the fact that BioMarin has multiple commercial-phase treatments, one of which is new to the market, sales reports ahead have the potential to turn into positive catalysts. Moreover, investors should watch valoctocgene roxaparvovec and the rest of the company’s robust pipeline for more opportunities ahead.

Horizon Therapeutics (HZNP): Strong Sales Growth With A Potential Blockbuster Approval Coming Down The Line

Horizon Therapeutics is best known for Krystexxa, a treatment that has been approved for patients with gout. Sales of the drug have been the cause of headlines, with 2018 sales growing 65% to $258.9 million.

The company intends to expand the label on the drug to include patients with uncontrolled gout who also suffer from chronic kidney disease. In fact, in June, the company announced that it began a study evaluating the combination of Krystexxa with methotrexate in patients with uncontrolled gout.

The company also has two rare disease drugs on the market that are seeing strong growth in sales. Ravicti, the company’s treatment for certain inborn urea cycle disorders, saw 2018 sales growth of 17%, generating sales of $226.6 million. Procysbi, a treatment indicated for the prevention of buildup of cystine crystals in the kidney, saw 2018 sales growth of 12%, climbing to $154.9 million.

Nonetheless, the company’s next drug may be its biggest yet. Horizon Therapeutics is working on teprotumumab as a potential treatment for protrusion of the eye as a result of inflammation behind the eye.

The company reduced data in April showing a dramatic reduction in eye bulging. In fact, 78% of patients responded to the treatment at week 24. Only 7.1% of patients in the placebo arm saw a response.

As a result of the strong data, it is expected that Horizon Therapeutics will be submitting a new drug application to the FDA any time now, with a potential approval in the coming months.

All in all, with multiple clinical studies underway, strong sales growth, and a potential approval from the FDA on the horizon, there are several catalysts to look forward to ahead.

Audentes Therapeutics (BOLD): Showing Strength In Rare Muscle Diseases

Finally, we have Audentes Therapeutics. The gene therapy technology company’s primary point of focus is on the development of treatments for patients with rare muscular diseases.

The company’s lead program is a gene therapy program assessing a candidate known as AT-132. AT-132 is being developed as a potential option for X-linked myotubular myopathy, an ultra-rare neuromuscular disorder.

The disorder is known to be caused by mutations to the myotubularin gene and usually results in muscle weakness. In severe cases, the condition can lead to respiratory failure.

Nonetheless, data from Audentes suggests that AT-132 could result in sustained improvement in neuromuscular and respiratory function. In fact, during the study, 3 patients that were dependent on ventilators achieved ventilator independence.

The company is also developing several other candidates as potential options in large neuromuscular indications, including Pompe disease, Crigler-Najjar and Deuchenne muscular dystrophy.

With a regulatory submission expected with regard to AT-132 relatively soon, as well as several ongoing clinical studies, Audentes Therapeutics will likely present several opportunities ahead.

Final Thoughts

Clinical, regulatory, and commercial catalysts drive some of the largest moves that we see in the biotechnology sector. The stocks mentioned above not only have several catalysts ahead, but previous data, including clinical results, sales reports, and regulatory feedback, suggest that these catalysts will be positive. So, keep your eyes peeled. 

This article is a paid advertisement. For full disclosures click here.

By Joshua Rodriguez

© 2019 Copyright Joshua Rodriguez - All Rights Reserved

Disclaimer: The above is a matter of opinion provided for general information purposes only and is not intended as investment advice. Information and analysis above are derived from sources and utilising methods believed to be reliable, but we cannot accept responsibility for any losses you may incur as a result of this analysis. Individuals should consult with their personal financial advisors.

© 2005-2019 - The Market Oracle is a FREE Daily Financial Markets Analysis & Forecasting online publication.

Post Comment

Only logged in users are allowed to post comments. Register/ Log in